2016
TMIC-16. TUMOR-INFILTRATING MYELOID CELLS MEDIATE ADAPTIVE IMMUNE RESISTANCE IN GLIOBLASTOMA
Antonios J, Soto H, Everson R, Orpilla J, Shin N, Moughon D, Sedighim S, Treger J, Odesa S, Tucker A, Yong W, Cloughesy T, Prins R, Liau L. TMIC-16. TUMOR-INFILTRATING MYELOID CELLS MEDIATE ADAPTIVE IMMUNE RESISTANCE IN GLIOBLASTOMA. Neuro-Oncology 2016, 18: vi203-vi203. DOI: 10.1093/neuonc/now212.856.Peer-Reviewed Original ResearchPD-1 mAbPD-1/PD-L1PD-1Immune responseDendritic cellsMAb blockadeColony stimulating factor 1 receptor inhibitorTumor lysate-pulsed dendritic cellsProgrammed death-1/ligand-1Cytolysis of tumor cellsMurine in vivo studiesDC vaccine treatmentAdaptive immune resistanceExpressed PD-L1Cell populationsVaccine treatmentTreatment to miceDominant mediatorIn vitro cytotoxicity assayTIL populationsPD-L1TIL infiltrationGL261 tumorsReceptor inhibitorsTumor microenvironment
2015
TMIC-04THERAPEUTIC ANTI-GLIOMA IMMUNITY IS DEPENDENT ON VACCINATION-INDUCED T CELL RESPONSES AND INHIBITION OF iAPC FUNCTION IN THE TUMOR MICROENVIRONMENT
Antonios J, Soto H, Orpilla J, Shin N, Everson R, Liau L, Prins R. TMIC-04THERAPEUTIC ANTI-GLIOMA IMMUNITY IS DEPENDENT ON VACCINATION-INDUCED T CELL RESPONSES AND INHIBITION OF iAPC FUNCTION IN THE TUMOR MICROENVIRONMENT. Neuro-Oncology 2015, 17: v214-v215. PMCID: PMC4639289, DOI: 10.1093/neuonc/nov236.04.Peer-Reviewed Original ResearchAdjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response
Antonios J, Soto H, Orpilla J, Shin N, Everson R, Liau L, Prins R. Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response. Journal For ImmunoTherapy Of Cancer 2015, 3: p393. PMCID: PMC4652564, DOI: 10.1186/2051-1426-3-s2-p393.Peer-Reviewed Original Research
2014
IT-01PD1/PDL1 INTERACTIONS MEDIATE SUPPRESSION OF ANTI-TUMOR IMMUNE ACTIVITY IN GLIOMA
Antonios J, Soto H, Harris R, Nathanson D, Sadeghi S, Ellingson B, Liau L, Prins R. IT-01PD1/PDL1 INTERACTIONS MEDIATE SUPPRESSION OF ANTI-TUMOR IMMUNE ACTIVITY IN GLIOMA. Neuro-Oncology 2014, 16: v110-v110. PMCID: PMC4218227, DOI: 10.1093/neuonc/nou258.1.Peer-Reviewed Original ResearchProgrammed death-1Tumor-infiltrating lymphocytesPost-implant dayCombination groupPD-1Tumor microenvironmentLymph nodesTreatment groupsEffective anti-tumor immune responseFACS analysisAnti-tumor immune activityAnti-tumor immune responseIncreased tumor-infiltrating lymphocytesAnti-PD1 mAbNegative costimulatory moleculesPD-1 mAbDendritic cell vaccinesAnti-tumor responsesImmunocompetent C57BL/6 miceTumor-bearing hemisphereDecreased tumor volumeGL261 glioma cellsCombined treatment groupAntitumor responseDeath-1Chronic inflammation drives glioma growth: cellular and molecular factors responsible for an immunosuppressive microenvironment
Ha E, Antonios J, Soto H, Prins R, Yang I, Kasahara N, Liau L, Kruse C. Chronic inflammation drives glioma growth: cellular and molecular factors responsible for an immunosuppressive microenvironment. Neuroimmunology And Neuroinflammation 2014, 1: 66-76. DOI: 10.4103/2347-8659.139717.Peer-Reviewed Original ResearchImmunosuppressive microenvironmentTumor massPatient's own immune systemGrade of malignancyCell typesCharacteristics of gliomasTumor microenvironmentGene therapyInflammatory microenvironmentChronic inflammationGlioma patientsImmune systemGliomaGlioma growthDisease initiationMicroenvironmentTumorMolecular factorsPatientsCellsMalignancyTherapyInflammationClearanceImmune-